Crescent Biopharma CBIO
NASDAQ CBIO
$13.92 +0.27 (+1.98%)
At close: Nov 10, 2026 · 4:00 PM EST

Crescent Biopharma (CBIO) Non Operating Interest Expenses (2024 - 2025)

Updated

Crescent Biopharma's Non Operating Interest Expenses came in at $2.19 million for FY2025.

Analysis

Crescent Biopharma (CBIO) Non Operating Interest Expenses (2024 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 217.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -477.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 653.00 Mn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 269.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Crescent Biopharma 386.36 Mn -320.93 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 1.07 Mn
Mar 31, 2025 1.11 Mn
Dec 31, 2024 852,000.00
API Access

Crescent Biopharma Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=CBIO&period=max&api_key=YOUR_API_KEY